SARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations
Abstract
Intravenous immunoglobulin (IVIG) preparations, used for the treatment of antibody deficiencies, provide a glimpse of the general population’s antibody profile as each preparation is generated from a pool of thousands of donors. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease 2019 (Covid-19) pandemic, and a vaccine for the prevention of Covid-19 was authorized for emergency use in December 2020. We completed a longitudinal analysis of SARS-CoV-2 antibody levels in commercial IVIG preparations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 29, 2022
- Source ID
- 10.1093/milmed/usac192
Entities
People
- Hyun J Park
- Karl C Alcover
- Qing Wang
- Satyen M Gada
Organizations
- Uniformed Services University of the Health Sciences
- Walter Reed National Military Medical Center